October 2024

October 2024 – As Atlanthera finalizes its regulatory preclinical package and prepares for the first-in-human clinical trial of its promising lead compound (12b80, HBP-doxorubicin) treating osteosarcoma, the Team continues to expand its innovative portfolio.
In parallel of collaborative research with the The University of Sheffield to advance a new molecule targeting metastatic breast cancer, Atlanthera is developing additional HBP-targeted active ingredients to address inflammatory diseases (18A184) and cancer.

Today, we’re thrilled to announce a new publication in ACS Publications featuring Atlanthera’s novel bone-targeted prodrug 1102–39. This prodrug is designed to enhance the therapeutic impact of methotrexate (MTX). Currently used as a medication that treats inflammatory arthritis, psoriasis and other inflammatory conditions, this prodrug can vectorize MTX within bone tissues while reducing systemic toxicity, a significant step forward in precision medicine for bone-related conditions.

« 𝘋𝘦𝘴𝘪𝘨𝘯, 𝘚𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘴, 𝘢𝘯𝘥 𝘊𝘩𝘢𝘳𝘢𝘤𝘵𝘦𝘳𝘪𝘻𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘏𝘉𝘗-𝘝𝘦𝘤𝘵𝘰𝘳𝘪𝘻𝘦𝘥 𝘔𝘦𝘵𝘩𝘰𝘵𝘳𝘦𝘹𝘢𝘵𝘦 𝘗𝘳𝘰𝘥𝘳𝘶𝘨 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘦 1102–39: 𝘌𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘐𝘯 𝘝𝘪𝘵𝘳𝘰 𝘊𝘺𝘵𝘰𝘵𝘰𝘹𝘪𝘤𝘪𝘵𝘺 𝘈𝘤𝘵𝘪𝘷𝘪𝘵𝘺 𝘪𝘯 𝘊𝘦𝘭𝘭 𝘊𝘶𝘭𝘵𝘶𝘳𝘦 𝘔𝘰𝘥𝘦𝘭𝘴, 𝘗𝘳𝘦𝘭𝘪𝘮𝘪𝘯𝘢𝘳𝘺 𝘐𝘯 𝘝𝘪𝘷𝘰 𝘚𝘢𝘧𝘦𝘵𝘺 𝘢𝘯𝘥 𝘌𝘧𝘧𝘪𝘤𝘢𝘤𝘺 𝘙𝘦𝘴𝘶𝘭𝘵𝘴 𝘪𝘯 𝘙𝘰𝘥𝘦𝘯𝘵𝘴 »

Direct full publication >

Direct link to the Publication >